Your session is about to expire
← Back to Search
Dermatology Consultation for Cellulitis
N/A
Waitlist Available
Led By Daniela Kroshinsky, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 weeks after patient discharge
Awards & highlights
Study Summary
This trial will compare patients who are evaluated by a dermatologist in addition to a hospitalist to those who are only evaluated by a hospitalist when admitted to the hospital, in order to demonstrate that early dermatology consultation reduces hospital length of stay, readmission rates, cost, antibiotic usage, and prevalence of pseudocellulitis.
Who is the study for?
This trial is for adults who can consent and follow study procedures, with a presumed diagnosis of cellulitis by the medical team. It excludes those under 18, pregnant women, prisoners, patients with certain infections or recent transplants, on high-dose steroids, or with abnormal vital signs.Check my eligibility
What is being tested?
The study compares standard care by internal medicine hospitalists to care that includes an early dermatology consult within 24 hours of admission for cellulitis. The goal is to see if this reduces hospital stay length, readmission rates, costs and antibiotic use.See study design
What are the potential side effects?
Since the intervention involves consultation rather than medication changes or new treatments directly administered to patients, no direct side effects are expected from the dermatology consult itself.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ will be measured at day of patient discharge
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~will be measured at day of patient discharge
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Antibiotic usage
Secondary outcome measures
Length of hospital stay
Other outcome measures
Readmission rate
Trial Design
2Treatment groups
Active Control
Group I: Dermatology ConsultActive Control1 Intervention
The patients randomized to the treatment group will obtain a dermatology evaluation within 24 hours of being admitted to MGH for their cellulitis. The skin and lymph node exam performed by the dermatologist on patients in the treatment group will be documented in the LMR for the subjects' medical records. Patients who are readmitted for cellulitis within one month of being discharged from the hospital will be considered treatment failures. Patients in the treatment group will have a follow-up visit in dermatology clinic within two weeks after being discharged. There will also be a medical record review performed one month after the patient's initial discharge from the hospital to assess for readmission.
Group II: No consultActive Control1 Intervention
Those who are in the control group will follow internal medicine hospitalist recommendations alone which will include when and what type of post-discharge follow-up appointments the patient will have. We would like to emphasize that as part of the standard of care, patients in the control arm may still receive a dermatology consult if it is deemed necessary and/or requested. We will not prevent patients or the patient's team of caregivers from requesting a dermatology consultation during the course of hospitalization. A follow-up phone call will be performed two weeks after discharge for patients in the control group in order to confirm the patient's outcome. There will also be a medical record review one month after the patient's initial discharge from the hospital to assess for readmission
Find a Location
Who is running the clinical trial?
Massachusetts General HospitalLead Sponsor
2,928 Previous Clinical Trials
13,198,109 Total Patients Enrolled
1 Trials studying Cellulitis
29 Patients Enrolled for Cellulitis
Dermatology FoundationOTHER
4 Previous Clinical Trials
113 Total Patients Enrolled
Daniela Kroshinsky, MDPrincipal InvestigatorMassachusetts General Hospital
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have an infection around any medical devices or tubes in your body.I am younger than 18 years old.I had a transplant less than 6 months ago or faced rejection in the last 3 months.I have been diagnosed with osteomyelitis.I have not used antithymocyte globulin or campath in the last 6 months, nor taken more than 20 mg/day of prednisone for over 30 days.I have been bitten by a human or animal.I am unable to make my own medical decisions.I have an infection or abscess at a surgery site.My doctor thinks I have cellulitis.Your blood pressure, heart rate, breathing rate, or temperature is not within the normal range.
Research Study Groups:
This trial has the following groups:- Group 1: Dermatology Consult
- Group 2: No consult
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is enrollment in this research experiment still available?
"The trial specified on clinicaltrials.gov is no longer searching for participants; the original post date was October 1st 2012 and it has not been updated since April 4th 2023. However, there are 6 other active medical trials recruiting patients at this time."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger